作者: Sara De Iudicibus , Gabriele Stocco , Stefano Martelossi , Margherita Londero , Egle Ebner
DOI: 10.1097/MCG.0B013E3181E8AE93
关键词:
摘要: BackgroundGlucocorticoids (GCs) are used in moderate-to-severe inflammatory bowel diseases (IBD) but their effect is often unpredictable.AimTo determine the influence of 4 polymorphisms GC receptor [nuclear subfamily 3, group C, member 1 (NR3C1)], interleukin-1β (IL-1β), and NACHT le